SCHEMBL23980801

SCHEMBL23980801

O=C(COc1c(Br)cccc1Br)c1ccc(Cl)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.44
KCNQ3 O43525 2/20 0.40
KCNQ2 O43526 2/20 0.40
KCNE1 P15382 2/20 0.40
KCNQ1 P51787 2/20 0.40
KCNQ5 Q9NR82 1/20 0.40
NPC1 O15118 2/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
AGTR1 P30556 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30217474 1.00 GRM4 (0.44) GRM4KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL23980850 0.79 MAPT (0.52) GRM4NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL5458228 0.76 SLC6A4 (0.44) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5
SCHEMBL23980841 0.76 NPC1 (0.50) GRM4NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL23980856 0.75 RAB9A (0.45) GRM4NPC1HTTRAB9ASMN1; SMN2
SCHEMBL30217421 0.75 RAB9A (0.45) GRM4NPC1HTTRAB9ASMN1; SMN2
SCHEMBL3973133 0.74 GSK3B (0.55) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5
SCHEMBL29499477 0.74 GSK3B (0.55) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5
SCHEMBL20703151 0.74 ALDH1A1 (0.49) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5
SCHEMBL10780708 0.74 RAB9A (0.46) KCNQ3KCNQ2KCNE1KCNQ1KCNQ5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4143183-B1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-10-22 EP disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
CN-115667250-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-01-31 CN disclosed
WO-2021219019-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR GRM4 2338/4885KCNQ3 1315/4885KCNQ2 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.